RVPHOTCPharmaceutical PreparationsFiscal year ends December 31
REVIVA PHARMACEUTICALS HOLDINGS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.45−0.02 (-4.36%)
Close on Oct 19, 2026
- Market cap
- $5.94M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$11.0420 (−96.08%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $5.94M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.39
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$13.02M
- EPS, diluted
- -$2.32
- Book value per share
- $1.15
- Diluted shares
- 13M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Operating income
-$13.48M
Net income
-$13.02M
EPS, diluted
-$2.32
Reported periodTrailing twelve months